Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE. Methods: This retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10–100 ng/mL, 100–500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups. Results: This study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels. Conclusion: High PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.
Abstract
Background/Aims: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE. Methods: This retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10–100 ng/mL, 100–500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups. Results: This study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels. Conclusion: High PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.
참고문헌 (23)
- Asciak R, "Malignant pleural effusion : from diagnostics to therapeutics", Clin Chest Med, 39, pp.181~193 (2018)
- Wang S, "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung", Lung Cancer, 135, pp.116~122 (2019)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
- Liu L, "Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients", Curr Oncol, 29, pp.77~93 (2021)
- Gao XC, "18F-FDG PET", CT SUVmax and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer, 2020, pp.20, 61~
- Feng LX, "Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma", Clin Transl Oncol, 21, pp.1005~1013 (2019)
- Zhu WY, "Epidermal growth factor receptor mutations and their prognostic value with carcinoembryonic antigen in pathological T1 lung adenocarcinoma", Dis Markers, 2018, pp.2942618~ (2018)
- Cai Z, "Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients", Onco Targets Ther, 9, pp.3873~3878 (2016)
- Zhang Y, "Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma", Tumour Biol, 35, pp.4921~4928 (2014)
- Feller-Kopman D, "Pleural disease", N Engl J Med, 378, pp.740~751 (2018)
- Lv YL, "Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma : a predictive marker for EGFR mutation", Transl Cancer Res, 8, pp.1027~1034 (2019)
- Zhao W, "Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer", Front Oncol, 12, pp.912505~ (2022)
- Han HS, "EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions : discordance in pleural metastases", Clin Lung Cancer, 12, pp.380~386 (2011)
- Chiang CL, "Cytology-based specimen triage for epidermal growth factor receptor mutation testing of malignant pleural effusions in non-small cell lung cancer", Front Oncol, 12, pp.810124~ (2022)
- Song Z, "Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients", Lung Cancer, 136, pp.23~29 (2019)
- Villena V, "Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15. 3and CA 72. 4", Lung Cancer, 40, pp.289~294 (2003)
- Porcel JM, "Use of a panel of tumor markers(carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments)in pleural fluid for the differential diagnosis of benign and malignant effusions", Chest, 126, pp.1757~1763 (2004)
- Han J, "The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm", Biomed Rep, 7, pp.61~66 (2017)
- Yanwei Z, "Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations", J Cancer Res Ther, 12, pp.254~258 (2016)
- Okamoto T, "Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer", Eur J Cancer, 41, pp.1286~1290 (2005)
- Passaro A, "Understanding EGFR heterogeneity in lung cancer", ESMO Open, 5, pp.e000919~ (2020)
- Marusyk A, "Tumor heterogeneity : causes and consequences", Biochim Biophys Acta, 1805, pp.105~117 (2010)